LEADERSHIP

DR. GIL FEILER

Dr. Feiler, 62, is a world-renowned economist and currently serves also as the company’s Head of Advisory Board. Dr. Feiler holds a PhD in Middle East Economics from Tel Aviv University, and is a graduate of the International Management Program at the Israeli Institute of Technology, Technion. Dr. Feiler currently serves also as Director of the Bank of Georgia for the Middle East and North Africa, as Partner at Forest Investment House ($1B AUM).

PROF. CAROLINE ROBERT (MD)

Prof. Caroline Robert, M.D., Ph.D., is Head of the Dermatology Unit at Institut Gustave Roussy in Paris, France. She is also co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. Prof. Robert received her medical training at Paris V University in France, and later completed a research fellowship in Cancer Immunology and Immunotherapy at Harvard, Brigham & Women's Hospital. Prof. Robert is the former Chair of the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC), and is currently a Board member of the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French Society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR).

PROF. ZAMIR HALPERN (MD)

Prof. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, served as Chairman of the Israeli Association of the Study of Liver, Chairman of the Israeli Gastroenterology Association, Chairman of the National Council for Food and Agriculture and is now Chairman of the National Gastro Nutrition and Liver Diseases Council at the Ministry of Health.

PROF. AMOS TOREN (MD)

Prof. Amos Toren is the Director of Pediatric Hemato- Oncology and BMT department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology,Sackler school of medicine tel-aviv university. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-oncology. He also has a Ph.D degree in genetics and qualified as a master of health administration (MHA) at the Recannati Business School, Tel-Aviv University.

Prof. Noam Shomron

Professor Noam Shomron is passionate about using basic science to advance better healthcare. Professor Shomron heads the Functional Genomic Team at the Faculty of Medicine at Tel Aviv University, after training at MIT. He leads a multidisciplinary team of scientists that develops computational methods for parsing big data in the bio-medical field using Artificial Intelligence. Shomron applied for more than 30 patents, published close to 200 peer-reviewed publications on multiple genomic fields including medicine, agriculture, and business.

Dr. SIGAL TAVOR (MD)

Dr. Tavor currently serves as a Senior Physician at the Hemato Oncology Institute, Assuta Medical Center, Tel-Aviv, Israel, and conducting Gene Therapy research at the Weizmann Institute, Israel. Dr. Tavor is the former Acting Head of the Leukemia Unit, Department of Hematology and Bone Marrow Transplantation, Sourasky Medical Center, Tel Aviv, Israel, where she worked for 20 years. Dr. Tavor has completed two postdoctoral fellowships: at the Department of Hematology and Oncology, University of California Los Angeles, CA, and at the Department of Immunology, Weizmann Institute, Israel. Dr. Tavor has published extensively on Leukemia in peer reviewed journals and is a member of the Israel Society of Hematology and Blood Transfusion, the European Hematology Association (EHA), the American Society of Hematology (ASH), and the European Leukemia Network (ELN).

DR. EREZ SCAPA (MD)

Dr. Scapa earned his M.D in 2000 at the Technion Institute of Technology in Haifa, Israel, cum laude. He later held a Research Fellowship in Hepatology at the Brigham and Women’s Hospital, Harvard University, Boston, MA, as well as a fellowship in Endoscopic Submucosal Dissection at the NTT Medical Center in Tokyo, Japan. He is an expert in invasive Endoscopy and has extensive experience in performing colonoscopies and gastroscopies. He is proficient in both diagnostic as well as invasive Endoscopic US (EUS) and serves as the head of the Endoscopic Submucosal Dissection (ESD) program in Tel-Aviv Sourasky Medical Center, initiated in 2019.

DR. DANA BEN-AMI SHOR (MD)

Dr. Ben-Ami Shor is a recognized expert in invasive endoscopy and gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel. Dr. Ben-Ami Shor earned her M.D in 2009, graduating cum laude from the Sackler Faculty of Medicine, Tel Aviv University. She specialized in internal medicine and gastroenterology at the Sheba Medical Center, Israel. She also successfully completed an advanced endoscopy (ASGE) accredited fellowship within the Center for Interventional Endoscopy at AdventHealth, in Florida. Additionally, Dr. Ben-Ami Shor is proficient in both diagnostic and therapeutic endoscopic ultrasound (EUS), and endoscopic retrograde cholangiopancreatography (ERCP).

DR. SIGALIT ARIELI PORTNOY

Dr. Sigalit Ariely-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro Pharmaceutical Industries LTD as Operation Group Vice President and in Teva Pharmaceutical industries LTD as OSD plant manager. In the last 7 years, Sigalit is the CEO of GSAP, the largest consulting company for pharmaceutical and medical device companies in Israel. Sigalit Ariely-Portnoy has a BSC and Ph.D in Chemical Engineering and MSC in Bio-Medical engineering from the Technion – Israel Institute of Technology, Haifa, Israel. regulatory aspects, risk assessment and more.

DR. TAL MOFKADI

Dr. Mofkadi holds a Ph.D in Financial Economics from Tel Aviv University. He is a lecturer at Tel Aviv University, the Interdisciplinary Center in Herzliya and universities abroad. He is the author of ‘The Handbook of Corporate Valuation’. Dr. Mofkadi provides expert opinions in financing, economic, and legal proceedings, writing valuations and optimal pricing policies as well as economic analysis of competition and regulatory aspects, risk assessment and more.